<DOC>
	<DOC>NCT01202227</DOC>
	<brief_summary>The purpose of this study is to assess the safety of the long-term use of pregabalin at doses up to 600 mg/day in patients with central neuropathic pain (post spinal cord injury pain, post stroke pain, and multiple sclerosis pain).</brief_summary>
	<brief_title>An Open-Label Long-Term Study Of Pregabalin For The Treatment Of Central Neuropathic Pain</brief_title>
	<detailed_description />
	<mesh_term>Wounds and Injuries</mesh_term>
	<mesh_term>Spinal Cord Injuries</mesh_term>
	<mesh_term>Neuralgia</mesh_term>
	<mesh_term>Spinal Cord Diseases</mesh_term>
	<mesh_term>Pregabalin</mesh_term>
	<criteria>Inclusion criteria for subjects to be shifted from Study A0081107 Subjects who completed the 18week study period in Study A0081107 conducted for chronic neuropathic pain after spinal cord injury; Subjects who completed assessments of all efficacy endpoints until the end of the treatment phase of the preceding Study A0081107 (V7); Inclusion criteria for subjects to be new participants in this study Subjects with central neuropathic pain after stroke or multiple sclerosis; At least 6 months have passed after the onset of central neuropathic pain; Pain VAS at least 40mm in Visit 1 and Visit 2; Creatinine clearance &lt; 60 mL/min; Platelet count &lt; 100 Ã— 103/mm3 ; White blood cell (WBC) count &lt; 2500 / mm3; Neutrophil count &lt; 1500/ mm3; Subjects who are expected to require surgery during the trial;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>Central Nervous System Diseases</keyword>
	<keyword>Therapeutic Uses</keyword>
	<keyword>Wounds and Injuries</keyword>
	<keyword>Trauma</keyword>
	<keyword>Nervous System</keyword>
	<keyword>pregabalin</keyword>
</DOC>